EL7.AI
StocksMedium•3 November 2026•
3 min read

Metropolis Healthcare revenue rises 15.8% to ₹496.8 crore in Q2

Key Facts

1Revenue rose 15.8% to ₹496.8 crore in the second quarter of FY2027.
2Net profit was ₹75.5 crore, up 42.7% year on year.
3The margin on earnings before interest, tax, depreciation and amortisation reached 27.2%, up 180 basis points.
4Consumer services revenue grew 17% to ₹289 crore, and corporate services revenue rose 15% to ₹208 crore.
5The board declared an interim dividend of ₹1 per share.

Metropolis Healthcare reported a 15.8% year-on-year increase in revenue from operations to ₹496.8 crore in the second quarter of FY2027, according to an investor presentation accompanying the company’s BSE filing. Net profit was ₹75.5 crore, up 42.7% from the year-earlier period, the same presentation showed. Profit growth outpaced revenue growth, alongside an improvement in the operating margin and expansion across the company’s channels and specialty segments. The presentation showed earnings before interest, tax, depreciation and amortisation at ₹134.9 crore, up 23.9% year on year. Its margin rose to 27.2% from 25.4%, an increase of 180 basis points.

By business channel, revenue from consumer-facing services rose 17% year on year to ₹289 crore, while revenue from services provided to businesses increased 15% to ₹208 crore, according to the results announcement carried by EquityBulls. The figures show revenue growth across both sides of the diagnostics business, with the consumer-facing channel growing slightly faster than the corporate channel. Revenue from Truhealth services also rose 20% to ₹86 crore. Revenue from medical specialties increased 20% to ₹198 crore. Managing Director Surendran Chemmenkotil said growth spanned the consumer and corporate channels, as well as Truhealth and specialties, supported by higher test volumes and network expansion.

Revenue growth coincided with a 6% year-on-year increase in average revenue per patient to ₹1,221 and a 5% rise in average revenue per test to ₹572, according to the results announcement. Revenue from cities classified as tier III rose about 20% year on year, making them the company’s fastest-growing markets during the quarter. Metropolis’ network reached about 750 towns through 5,119 service points. These indicators show geographic coverage expanding alongside revenue per patient and per test. Chemmenkotil said the company plans to expand its presence in tier II and tier III towns and increase preventive health and specialty offerings during the rest of the financial year.

For comparison, revenue from operations in the first quarter of FY2027 was about ₹450.2 crore, up 16.6% year on year, according to the company’s results release for that quarter. Patient volumes in the first quarter also rose 10% year on year, and test volumes increased 11%. In the second quarter, the presentation reported growth in revenue, profit and margin, while Chemmenkotil said higher test volumes were among the factors supporting results. The board declared an interim dividend of ₹1 per share on November 3, 2026. The managing director said the company would continue expanding its presence in smaller cities and strengthening preventive health and specialty services during the rest of the financial year.